Systematic review of interventions for depression and anxiety in persons with inflammatory bowel disease

被引：33

作者：

Fiest K.M. ^{[1
,8
]}

Bernstein C.N. ^{[1
]}

Walker J.R. ^{[2
]}

Graff L.A. ^{[2
]}

Hitchon C.A. ^{[1
]}

Peschken C.A. ^{[1
]}

Zarychanski R. ^{[1
,3
]}

Abou-Setta A. ^{[3
]}

Patten S.B. ^{[4
]}

Sareen J. ^{[5
]}

Bolton J. ^{[5
]}

Singer A. ^{[6
]}

Marrie R.A. ^{[1
,7
]}

机构：

[1] Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 820 Sherbrook Street, Winnipeg

[2] Department of Clinical Health Psychology, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 771 Bannatyne Avenue, Winnipeg

[3] George and Fay Yee Centre for Health Care Innovation, University of Manitoba, 820 Sherbrook Street, Winnipeg

[4] Departments of Community Health Sciences and Psychiatry, Cumming School of Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary

[5] Department of Psychiatry, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 771 Bannatyne Avenue, Winnipeg

[6] Department of Family Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 770 Bannatyne Avenue, Winnipeg

[7] Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, 820 Sherbrook Street, Winnipeg

[8] Health Sciences Centre, 820 Sherbrook Street, Winnipeg, R3A 1R9, MB

来源：

BMC Research Notes | / 9卷 / 1期

基金：

加拿大健康研究院;

关键词：

Anxiety; Depression; Inflammatory bowel disease; Systematic review;

D O I：

10.1186/s13104-016-2204-2

中图分类号：

学科分类号：

摘要：

Background: Depression and anxiety are common in inflammatory bowel disease (IBD) and can affect disease outcomes, including quality of life and success of disease treatment. Successful management of psychiatric comorbidities may improve outcomes, though the effectiveness of existing treatments in IBD is unknown. Methods: We searched multiple online databases from inception until March 25, 2015, without restrictions on language, date, or location of publication. We included controlled clinical trials conducted in persons with IBD and depression or anxiety. Two independent reviewers reviewed all abstracts and full-text articles and extracted information including trial and participant characteristics. We also assessed the risk of bias. Results: Of 768 unique abstracts, we included one trial of pharmacological anxiety treatment in IBD (48 participants), which found an improvement in anxiety symptoms (p < 0.001). There was a high risk of bias in this trial. We found no controlled clinical trials on the treatment of depression in persons with IBD and depression and no controlled clinical trials reporting on psychological interventions for anxiety or depression in IBD. Conclusions: Only one trial examined an intervention for anxiety in adults with IBD and no trials studied depression in adults with IBD. The level of evidence is low because of the risk of bias and limited evidence. © 2016 The Author(s).

引用

共 30 条

[1] Kaplan G.G., The global burden of IBD: From 2015 to 2025, Nat Rev Gastroenterol Hepatol., 12, 12, pp. 720-727, (2015)
[2] Bernstein C.N., Wajda A., Svenson L.W., MacKenzie A., Koehoorn M., Jackson M., Et al., The epidemiology of inflammatory bowel disease in Canada: A population-based study, Am J Gastroenterol, 101, 7, pp. 1559-1568, (2006)
[3] Bernstein C.N., Blanchard J.F., Rawsthorne P., Wajda A., Epidemiology of Crohn's Disease and ulcerative colitis in a central Canadian Province: A population-based study, Amer J Epidemiol., 149, 10, pp. 916-924, (1999)
[4] Arroll B., Macgillivray S., Ogston S., Reid I., Sullivan F., Williams B., Et al., Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: A meta-analysis, Ann Fam Med., 3, 5, pp. 449-456, (2005)
[5] Eberhardt K., Larsson B.M., Nived K., Lindqvist E., Work disability in rheumatoid arthritis-development over 15 years and evaluation of predictive factors over time, J Rheumatol, 34, 3, pp. 481-487, (2007)
[6] Wiles N.J., Dunn G., Barrett E.M., Harrison B.J., Silman A.J., Symmons D.P., One year followup variables predict disability 5 years after presentation with inflammatory polyarthritis with greater accuracy than at baseline, J Rheumatol, 27, 10, pp. 2360-2366, (2000)
[7] Pollard L., Choy E.H., Scott D.L., The consequences of rheumatoid arthritis: Quality of life measures in the individual patient, Clin Exp Rheumatol, 23, 5, pp. S43-S52, (2005)
[8] Walker J.R., Ediger J.P., Graff L.A., Greenfeld J.M., Clara I., Lix L., Et al., The Manitoba IBD cohort study: A population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders, Am J Gastroenterol, 103, 8, pp. 1989-1997, (2008)
[9] Mittermaier C., Dejaco C., Waldhoer T., Oefferlbauer-Ernst A., Miehsler W., Beier M., Et al., Impact of depressive mood on relapse in patients with inflammatory bowel disease: A prospective 18-month follow-up study, Psychosom Med, 66, 1, pp. 79-84, (2004)
[10] Persoons P., Vermeire S., Demyttenaere K., Fischler B., Vandenberghe J., Van Oudenhove L., Et al., The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab, Aliment Pharmacol Ther, 22, 2, pp. 101-110, (2005)

← 1 2 3 →